Solid Tumors clinical trials
Showing 251–300 of 1,133 active trials. Describe your situation to see which ones look like a fit.
- A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy
- A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
- First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
- EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
- A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- COAST Therapy in Advanced Solid Tumors and Prostate Cancer
- A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
- Study of SGR-3515 In Participants With Advanced Solid Tumors.
- A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
- Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
- Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
- Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors
- Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
- A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
- A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
- SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
- First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
- A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
- QTX3034 in Patients With KRAS G12D Mutation
- A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
- An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
- A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
- HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
- A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
- Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
- First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
- A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
- SNV4818 in Participants With Advanced Solid Tumors
- Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
- First In Human Study of CX-2051 in Advanced Solid Tumors
- Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
- A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
- Palbociclib and Pembrolizumab In Central Nervous System Metastases
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
- A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
- A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
- A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- A Study of ASP3082 in Adults With Advanced Solid Tumors
- A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.